Clinical trials: Dapagliflozin
Acute Myocardial Infarction, Heart Failure
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF)…
- Trial name
- DAPA-MI (NCT04564742)
- Testing
- Dapagliflozin
- Where
- 103 sites in Sweden, United Kingdom
- Volunteers
- 4,017 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
The purpose of this study is to demonstrate bioequivalence of coadministered drugs on healthy subjects.
- Trial name
- NCT02223065
- Testing
- Saxagliptin, Dapagliflozin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2…
- Trial name
- NCT01606007
- Testing
- Saxagliptin, Metformin XR, Dapagliflozin
- Where
- 139 sites in United States, Canada and 6 more
- Volunteers
- 1,282 people
- Sponsor
- AstraZeneca
Pancreas Cancer, Pancreatic Cancer
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT04542291
- Testing
- Dapagliflozin, BIOSENSE meters
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in Sweden to assess the effect of Omega-3 carboxylic acids and dapagliflozin on liver fat in patients with…
- Trial name
- EFFECTII (NCT02279407)
- Testing
- Omega-3 carboxylic acids, Dapagliflozin
- Where
- 5 sites in Sweden
- Volunteers
- 223 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can improve (decrease) blood glucose values in Asian patients with Type 2 Diabetes who have never been treated with medication or have been on…
- Trial name
- NCT01095653
- Testing
- Dapagliflozin, Metformin
- Where
- 39 sites in China, India and 2 more
- Volunteers
- 1,179 people
- Sponsor
- AstraZeneca
Alzheimer Disease
Dapagliflozin In Alzheimer's Disease
This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl aspartate (NAA) levels using magnetic…
- Trial name
- NCT03801642
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jeff Burns, MD
Type 2 Diabetes Mellitus
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with…
- Trial name
- NCT00859898
- Testing
- Dapagliflozin, Metformin XR
- Where
- 123 sites in United States, India and 4 more
- Volunteers
- 1,093 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with…
- Trial name
- NCT02433678
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University at Buffalo
Type 2 Diabetes Mellitus, High HbA1c Level
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.
- Conditions
- Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control
- Trial name
- NCT01392677
- Testing
- dapagliflozin
- Where
- 42 sites in Canada, Czechia and 4 more
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
This is a randomised, placebo-controlled, double-blind, parallel-group, international, multicentre, Phase IV study to investigate the effects of dapagliflozin on cardiac substrate uptake, myocardial efficiency and myocardial…
- Trial name
- DAPACARD (NCT03387683)
- Testing
- dapagliflozin
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Polycystic Ovary Syndrome, Obesity
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin…
- Trial name
- NCT02635386
- Testing
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Woman's
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Type 2 Diabetes
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
The purpose of this study is to learn whether dapagliflozin, after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an angiotensin-converting enzyme…
- Trial name
- NCT01137474
- Testing
- Dapagliflozin
- Where
- 329 sites in United States, Canada and 14 more
- Volunteers
- 2,996 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Cardiovascular Disease
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added…
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
- Trial name
- NCT01031680
- Testing
- Dapagliflozin
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 922 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria.
- Trial name
- MIRO-CKD (NCT06350123)
- Where
- 92 sites in United States, Austria and 13 more
- Volunteers
- 324 people
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction
Dapagliflozin (DAPA) Effects in HFpEF
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and…
- Trial name
- NCT04730947
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Type II Diabetes
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin
- Trial name
- NCT02429258
- Testing
- Farxiga, Metformin, Insulin
- Where
- 26 sites in United States
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
PK Study of Dapagliflozin in Pediatric Subjects With T2DM
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT01525238
- Testing
- Dapagliflozin
- Where
- 17 sites in United States, Mexico
- Volunteers
- 53 people
- Sponsor
- AstraZeneca